Pharmacokinetics of alemtuzumab and the relevance in clinical practice

References

• Ravandi F, O'Brien S. Alemtuzumab. Expert Rev Anticancer Ther 2005; 5: 39–51
   PubMed Web of Science ®Google Scholar
• Mone A P, Cheney C, Banks A L, Tridandapani S, Mehter N, Guster S, et al. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia 2006; 20: 272–279
   PubMed Web of Science ®Google Scholar
• Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332: 323–327
   PubMed Web of Science ®Google Scholar
• Xia M Q, Hale G, Waldmann H. Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. Mol Immunol 1993; 30: 1089–1096
   PubMed Web of Science ®Google Scholar
• Demko S, Summers J, Keegan P, Pazdur R. FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia. Oncologist 2008; 13: 167–174
   PubMed Web of Science ®Google Scholar
• Campath (Alemtuzumab) full prescribing information. Bayer HealthCare Pharmaceuticals. 2007
   Google Scholar
• Hillmen P, Skotnicki A B, Robak T, Jaksic B, Dmoszynska A, Wu J, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007; 25: 5616–5623
   PubMed Web of Science ®Google Scholar
• Keating M J, Flinn I, Jain V, Binet J L, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554–3561
   PubMed Web of Science ®Google Scholar
• Osterborg A, Dyer M J, Bunjes D, Pangalis G A, Bastion Y, Catovsky D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European study group of CAMPATH-1H treatment in chronic lymphocytic leukemia. J Clin Oncol 1997; 15: 1567–1574
   PubMed Web of Science ®Google Scholar
• Rai K R, Freter C E, Mercier R J, Cooper M R, Mitchell B S, Stadtmauer E A, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002; 20: 3891–3897
   PubMed Web of Science ®Google Scholar
• Lundin J, Kimby E, Bjorkholm M, Broliden P A, Celsing F, Hjalmar V, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100: 768–773
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Winkler D, Buhler A, Zenz T, Groner S, Busch R, et al. Subcutaneous alemtuzumab (MabCampath) in fludarabine-refractory CLL (CLL2H Trial of the GCLLSG). [Abstract]. Blood 2007; 110: 918a
   Web of Science ®Google Scholar
• Elter T, Borchmann P, Schulz H, Reiser M, Trelle S, Schnell R, et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005; 23: 7024–7031
   PubMed Web of Science ®Google Scholar
• Faderl S, Thomas D A, O'Brien S, Garcia-Manero G, Kantarjian H M, Giles F J, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003; 101: 3413–3415
   PubMed Web of Science ®Google Scholar
• Pettitt A R, Matutes E, Oscier D. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia 2006; 20: 1441–1445
   PubMed Web of Science ®Google Scholar
• Montillo M, Tedeschi A, Miqueleiz S, Veronese S, Cairoli R, Intropido L, et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 2006; 24: 2337–2342
   PubMed Web of Science ®Google Scholar
• O'Brien S M, Kantarjian H M, Thomas D A, Cortes J, Giles F J, Wierda W G, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003; 98: 2657–2663
   PubMed Web of Science ®Google Scholar
• Wendtner C M, Ritgen M, Schweighofer C D, Fingerle-Rowson G, Campe H, Jager G, et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004; 18: 1093–1101
   PubMed Web of Science ®Google Scholar
• Giralt S. The role of alemtuzumab in nonmyeloablative hematopoietic transplantation. Semin Oncol 2006; 33: S36–S43
   PubMed Web of Science ®Google Scholar
• Morris P J, Russell N K. Alemtuzumab (Campath-1H): a systematic review in organ transplantation. Transplantation 2006; 81: 1361–1367
   PubMed Web of Science ®Google Scholar
• Jilani I, Keating M, Giles F J, O'Brien S, Kantarjian H M, Albitar M. Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay. Leuk Res 2004; 28: 1255–1262
   PubMed Web of Science ®Google Scholar
• Hale G, Rebello P, Brettman L R, Fegan C, Kennedy B, Kimby E, et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 2004; 104: 948–955
   PubMed Web of Science ®Google Scholar
• Rebello P, Hale G. Pharmacokinetics of CAMPATH-1H: assay development and validation. J Immunol Methods 2002; 260: 285–302
   PubMed Web of Science ®Google Scholar
• Mould D R, Baumann A, Kuhlmann J, Keating M J, Weitman S, Hillmen P, et al. Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol 2007; 64: 278–291
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Wierda W, Lapushin R, O'Brien S, Faderl S, Browning M L, et al. Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Eur J Haematol 2008; 80: 296–298
   PubMed Web of Science ®Google Scholar
• Elter T, Kilp J, Borchmann P, Schulz H, et al. Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia, Manuscript submitted
   Google Scholar
• Fischer K, Schweighofer C D, Ritgen M, Boettcher S, Scharf E, Eichhorst B F, et al. Dose escalation study to evaluate dose limiting toxicity (DLT), maximum tolerated dose (MTD) and safety of alemtuzumab for consolidation therapy in patients with chronic lymphocytic leukemia: phase I/II trial of the German CLL Study Group (GCLLSG). [Abstract]. Blood 2007; 110: 612a
   Web of Science ®Google Scholar
• Rebello P, Cwynarski K, Varughese M, Eades A, Apperley J F, Hale G. Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy 2001; 3: 261–267
   PubMed Web of Science ®Google Scholar
• Morris E C, Rebello P, Thomson K J, Peggs K S, Kyriakou C, Goldstone A H, et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Blood 2003; 102: 404–406
   PubMed Web of Science ®Google Scholar
• Oshima K, Kanda Y, Nakahara F, Shoda E, Suzuki T, Imai Y, et al. Pharmacokinetics of alemtuzumab after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab with or without CD52-positive malignancies. Am J Hematol 2006; 81: 875–879
   PubMed Web of Science ®Google Scholar
• Albitar M, Do K A, Johnson M M, Giles F J, Jilani I, O'Brien S, et al. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer 2004; 101: 999–1008
   PubMed Web of Science ®Google Scholar
• Smolewski P, Szmigielska-Kaplon A, Cebula B, Jamroziak K, Rogalinska M, Kilianska Z, et al. Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells. Leuk Lymphoma 2005; 46: 87–100
   PubMed Web of Science ®Google Scholar